The introduction of tumor necrosis factor (TNF) inhibitors in the late 1990s revolutionized the treatment of rheumatic diseases, such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA), providing patients with another therapeutic option when conventional therapies were ineffective. However, when these diseases fail to respond to anti-TNF therapy, it is still difficult to determine the next best course of action. Dr Christopher Ritchlin “One of the big challenges we have in treating psoriatic arthritis, and I would say rheumatoid arthritis was fine, is how to manage patients who have failed…
Read More